Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | LOX | P28300 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18339487 | 0.84 | ALOX5 (0.54) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL24244869 | 0.78 | ALOX5 (0.43) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL9602556 | 0.77 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1706446 | 0.74 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1444769 | 0.74 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL79534 | 0.74 | ALOX5 (0.54) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL29039574 | 0.73 | ALOX5 (0.50) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL17616755 | 0.73 | ALOX5 (0.42) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL17615212 | 0.72 | ALOX5 (0.41) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL9824749 | 0.71 | ALOX5 (0.53) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286996-A1 | PROCESS FOR THE PREPARATION OF ZILEUTON | DIPHARMA FRANCIS S.R.I. (IT) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286996-A1 | PROCESS FOR THE PREPARATION OF ZILEUTON | MPO, ZYX, F7 | ALOX5 420/4885CYP1A2 189/4885PTGES 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.